Odrel® (Clopidogrel) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Each tablet contains Clopidogrel Bisulfate INN equivalent to 75 mg Clopidogrel. Odrel® (Clopidogrel) is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction or established peripheral arterial disease.
Odrel Tablet 75 mg
Prevention of artherosclerotic events in peripheral arterial disease or after myocardial infarction or ischaemic stroke: 75 mg once daily.
Acute coronary syndrome (without ST-segment elevation): initially 300 mg then 75 mg daily.
Acute myocardial infarction (with ST-segment elevation): initially 300 mg then 75 mg daily; initial dose omitted if patient over 75 years.